TAFASITAMAB-CXIX

898 reported adverse events

These side effects are most commonly reported by patients taking TAFASITAMAB-CXIX:

# Side effect Count
0 DISEASE PROGRESSION 239
1 OFF LABEL USE 168
2 LYMPHOMA 166
3 DEATH 65
4 DRUG INEFFECTIVE 47
5 DIFFUSE LARGE B-CELL LYMPHOMA 42
6 NEUTROPENIA 39
7 BLOOD LACTATE DEHYDROGENASE INCREASED 38
8 MALIGNANT NEOPLASM PROGRESSION 37
9 COVID-19 30
See all common reactions for TAFASITAMAB-CXIX

TAFASITAMAB-CXIX is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CD19 EXPRESSION DECREASED 1 0.3333
1 CD19 ANTIGEN LOSS 2 0.1538
2 BLASTOCYSTIS INFECTION 5 0.0575
3 DIALYSIS DISEQUILIBRIUM SYNDROME 1 0.0500
4 COR PULMONALE CHRONIC 6 0.0324
5 CSF LYMPHOCYTE COUNT ABNORMAL 1 0.0278
6 CATHETER SITE THROMBOSIS 7 0.0263
7 RHODOCOCCUS INFECTION 4 0.0242
8 FULL BLOOD COUNT 1 0.0179
9 CITROBACTER TEST POSITIVE 1 0.0152
See all enriched reactions for TAFASITAMAB-CXIX